RxDoctor Payments Data

John Kelly, MD

Geriatric Medicine · Michigan City, INNPI 1033104849

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.5% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Novo Nordisk at 31.2% of the total.

$419in general payments, 2019–2025

Across 20 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$131
  • AbbVie$80
  • Gilead$71
  • Abbott$50
  • VOCO America Inc.$40
  • Novartis$24
  • plus $23 from 2 others

What the payments were for

  • Food & beverage$39694%
  • Education$123%
  • Gifts$113%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$419 in reported general payments places this provider in the 65th percentile of 70 geriatric medicine providers in Indiana.

See all geriatric medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$3,404
Medicare patients
66
Services billed
275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide97$95,147
EliquisApixaban52$48,690
MounjaroTirzepatide32$33,433
JardianceEmpagliflozin24$33,319
Combivent RespimatIpratropium/Albuterol Sulfate30$32,103
JanuviaSitagliptin Phosphate17$25,985
TradjentaLinagliptin26$24,291
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog38$19,047
EntrestoSacubitril/Valsartan16$18,337
Lantus SolostarInsulin Glargine,hum.Rec.Anlog80$17,508
LinzessLinaclotide11$16,140
Breo ElliptaFluticasone/Vilanterol22$15,689
Humulin R U-500 KwikpenInsulin Regular, Human13$14,601
SymbicortBudesonide/Formoterol Fumarate30$13,913
MyrbetriqMirabegron16$12,777

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$131$95,14797 claims
Lilly USA, LLCMounjaro$12$33,43332 claims
NovartisEntresto$24$18,33716 claims
AbbVieLinzess$80$16,14011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 70 geriatric medicine providers in Indiana.

Other geriatric medicine in Michigan City

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →